

TABLE 184: WITHDRAWAL DUE TO ADVERSE EVENT

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Buti et al., 2014 OPTIMIZE	1	(32) T12 PR24-48 RGT q8	1	371	0%
		(33) T12 PR24-48 RGT q12	0	369	0%
Dieterich et al., 2014-1	1	42) SIM12 PR24-48 RGT	0	53	0%
Ferenci et al., 2014 PEARL-III	1b	(14) PAR/RIT12 + OMB12 + DAS12	0	209	0%
Ferenci et al., 2014 PEARL-IV	1a	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	0	100	0%
Fried et al., 2013 PILLAR	1	(1) PR48	1	77	1%
		(42) SIM12 PR24-48 RGT	1	77	1%
Gane et al., 2013-1 ELECTRON	2+3	(3) SOF12 + RBV12	0	10	0%
		(40) SOF12 + PR12	0	11	0%
Gane et al., 2013-3 ELECTRON	1	(3) SOF12 + RBV12	0	25	0%
Gane et al., 2014-1 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	25	0%
Kowdley et al., 2013 ATOMIC	1	(40) SOF12 + PR12	1	52	2%
Kowdley et al., 2014 ION-3	1	(6) SOF12 + LDV12	0	216	0%
		(8) SOF8 + LDV8	0	215	0%
		(9) SOF8 + LDV8 + RBV8	0	216	0%
Lalezari et al., 2015	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	1	38	3%
Lawitz et al., 2013 NEUTRINO	1+4+5+6	(40) SOF12 + PR12	1	327	0%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%
		(8) SOF8 + LDV8	0	20	0%
		(9) SOF8 + LDV8 + RBV8	0	21	0%
Manns et al., 2014 QUEST-2	1	(1) PR48	0	134	0%
		(42) SIM12 PR24-48 RGT	0	257	0%
Osinusi et al., 2013 SPARE-1	1	(4) SOF24 + RBV24	0	10	0%
Osinusi et al., 2013 SPARE-2	1	(4) SOF24 + RBV24	0	25	0%
		(71) SOF24 + RBV (low dose) 24	0	25	0%
Sulkowski et al., 2014-1 ^a	2+3	(3) SOF12 + RBV12	1	68	1%
Sulkowski et al., 2014-2	1	(4) SOF24 + RBV24	0	115	0%
Sulkowski et al., 2014	1	(19) DCV12 + SOF12	0	41	0%
Zeuzem et al., 2015 C-EDGE	1+4+6	(22) GRZ12 + ELB12	3	316	1%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

^a Data for ineligible treatment for genotype 3, (3) SOF12 + RBV12, are included.